Viviane Lealdini1, Damila Cristina Trufelli2, Fernanda Borges Ferreira da Silva1, Savia Raquel Costa Normando1, Elisa Watanabe Camargo1, Leandro Luongo de Matos3, Fernando Luiz Affonso Fonseca4, Patricia Xavier Santi5, Auro Del Giglio1. 1. Department of Clinical Oncology, Faculdade de Medicina do ABC, Av. Principe de Gales, 821, CEP. 09060-650 Santo André, São Paulo, Brazil. 2. Department of Oncology and Hematology Discipline, Faculdade de Medicina do ABC, Av. Principe de Gales, 821, CEP. 09060-650 Santo André, São Paulo, Brazil. Electronic address: damilatrufelli@yahoo.com.br. 3. Department of Public Health, Faculdade de Medicina do ABC, Av. Principe de Gales, 821, CEP. 09060-650 Santo André, São Paulo, Brazil. 4. Department of the Clinical Laboratory, Faculdade de Medicina do ABC, Av. Principe de Gales, 821, CEP. 09060-650 Santo André, São Paulo, Brazil. 5. Department of Oncology and Hematology Discipline, Faculdade de Medicina do ABC, Av. Principe de Gales, 821, CEP. 09060-650 Santo André, São Paulo, Brazil.
Abstract
OBJECTIVES: To evaluate the relationship between inflammatory parameters through the modified Glasgow Prognostic Score (mGPS) and other clinical characteristics of elderly patients with cancer, including frailty evaluated by the Edmonton Frailty Scale (EFS). MATERIALS AND METHODS: We included patients from the oncology service at Faculdade de Medicina do ABC with a confirmed diagnosis of solid tumor aged 65 years or more at diagnosis. Patients were assessed by applying the translated and validated to Portuguese version of the EFS and also had blood sample collection for the evaluation of C-reactive protein (CRP) and albumin for calculation of the mGPS. RESULTS: We included 52 patients of both sexes, with median age of 72.5 years, of these 67.3% had localized disease and 32.7% metastatic disease. The mGPS presented 17.3% of high-risk patients. The frailty evaluated by EFS occurred in 57.6% of patients. Patients with both abnormal parameters (CRP and albumin) in the mGPS had significantly higher scores on EFS when compared to those with no change (6 vs. 9.56 points, p=0.021). The mGPS correlated also with clinical staging (p=0.019) and performance status (p=0.039). CONCLUSIONS: Inflammatory parameters correlate significantly with frailty, more advanced clinical stage and poor functional status.
OBJECTIVES: To evaluate the relationship between inflammatory parameters through the modified Glasgow Prognostic Score (mGPS) and other clinical characteristics of elderly patients with cancer, including frailty evaluated by the Edmonton Frailty Scale (EFS). MATERIALS AND METHODS: We included patients from the oncology service at Faculdade de Medicina do ABC with a confirmed diagnosis of solid tumor aged 65 years or more at diagnosis. Patients were assessed by applying the translated and validated to Portuguese version of the EFS and also had blood sample collection for the evaluation of C-reactive protein (CRP) and albumin for calculation of the mGPS. RESULTS: We included 52 patients of both sexes, with median age of 72.5 years, of these 67.3% had localized disease and 32.7% metastatic disease. The mGPS presented 17.3% of high-risk patients. The frailty evaluated by EFS occurred in 57.6% of patients. Patients with both abnormal parameters (CRP and albumin) in the mGPS had significantly higher scores on EFS when compared to those with no change (6 vs. 9.56 points, p=0.021). The mGPS correlated also with clinical staging (p=0.019) and performance status (p=0.039). CONCLUSIONS: Inflammatory parameters correlate significantly with frailty, more advanced clinical stage and poor functional status.